NCT05452889RecruitingEarly phase 1
PET Image in PAH Patients
Utilizing 18F-fluoroglutamine PET Imaging in Patients With Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
Pulmonary arterial hypertension (PAH) is mortal disease affecting the blood vessels of the lung. Despite its morbid prognosis, PAH is often misdiagnosed or ignored, with an average time of 44 months between onset of symptoms to diagnosis and substantial progression of disease severity. Therefore, a pressing need exists to develop non-invasive diagnostic imaging tools, particularly that can detect early disease stages. Efforts have been made to develop such imaging capabilities through platform development of echocardiography, cardiac MRI, chest computed tomography (CT), and positron emission tomography (PET), among others. While some have demonstrated promise, few have shown a precise ability to offer disease quantifications of the diseased lung and vasculature itself, to detect early stages of disease, and to reflect alterations of the lung, vasculature, and right ventricle that reflect the molecular origins of this disease. \[F-18\]FGln has been previously utilized in oncology studies as a non-invasive in vivo imaging biomarker of tumor glutamine flux and metabolism. Our preliminary in vivo pre-clinical rodent studies demonstrated that \[F-18\]FGln demonstrated increased uptake in diseased pulmonary vessels and the right ventricle in a rodent model of PAH. The proposed research study will provide preliminary evidence of the potential to utilize \[F-18\]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 71 (estimated)
- First submitted
- 9 Jun 2022
- Start date
- 11 Jul 2022
- Primary completion date
- Jan 2027
- Lead sponsor
- Stephen Y. Chan
- NCT number
- NCT05452889
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 71
- From 11 Jul 2022 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Working previously in any of the following "cool miner, painter, iron miner, Mill worker, asbestos, insulation/heat resistance materials, sand"
- Working previously in any of the following "coal miner, painter, iron miner, Mill worker, asbestos, insulation/heat resistance materials, sand"
Other illness
- History of CT contrast allergy
- History of radiation exposure at workplace
- Any medical conditions involving the heart or lungs that would make participation in the study unsafe in the opinion of the PI.
- Controls:
- History of CT contrast allergy.
- History of radiation exposure at workplace
- Any medical conditions involving the heart or lungs or that would make participation in the study unsafe in the opinion of the PI.
- Family history of Pulmonary Hypertension or Scleroderma
Other
- Cases:
- Smoking
- Pregnant/ breast feeding women
- Children under 18
- Inability to read and understand the informed consent
- Inability to lie down for long period of time
- Having claustrophobic
- Consuming more than 2-3 alcoholic drinks a week
- Smoking
- Pregnant/ breast feeding women
- Children under 18
- Inability to read and understand the informed consent
- Inability to lie down for long period of time
- Having claustrophobic
- Consuming more than 2-3 alcoholic drinks a week
Who the study is looking for
- Cases:
- Age between 18-75 years old
- Confirmed diagnosis of SSc-PAH / SSc-eiPAH/IPAH/ by right heart catheterization. And Scleroderma with no PAH confirmand by echo.
- Controls:
- Age between 18-75 years old
- Individuals who are at low risk for current or future cardiovascular or pulmonary symptoms or diseases
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Montefiore Hospital Clinical and Translational Research Center Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.